文献速递银屑病与炎症性皮肤病

新型TYK2抑制剂D-2570治疗中重度斑块状银屑病的2期随机对照试验

Novel TYK2 inhibitor D-2570 in moderate-to-severe plaque psoriasis: A randomized, double-blind, placebo-controlled, phase 2 trial.
PubMed 文献 · J Am Acad Dermatol · 2025-09-16

这项随机、双盲、安慰剂对照的2期研究(NCT06278350)将中重度斑块状银屑病患者按1:1:1:1随机分配至D-2570 18/27/36 mg或安慰剂组,每日一次治疗12周。第12周时,D-2570各剂量组的PASI 75、PASI 90、PASI 100及sPGA 0/1应答率均显著高于安慰剂,且耐受性良好,大多数治疗中出现的不良事件为轻中度。

要点

  • D-2570 18/27/36 mg组第12周PASI 75达85.0%至90.0%,安慰剂组为12.5%(P < .001)。
  • PASI 90为70.7%至77.5% vs 5.0%,PASI 100为39.0%至50.0% vs 2.5%。
  • D-2570耐受性良好,多数不良事件为轻中度,并可有效抑制IL-17A水平。

核心结论

  • D-2570在中重度斑块状银屑病患者中显示出高疗效和良好的安全性。

研究设计与样本

  • 随机、双盲、安慰剂对照的2期研究(NCT06278350),患者按1:1:1:1随机接受D-2570 18/27/36 mg或安慰剂每日一次治疗12周。

主要发现

  • 第12周PASI 75应答率:D-2570 18/27/36 mg组85.0%至90.0%,安慰剂组12.5%(P < .001)。
  • 第12周PASI 90应答率:70.7%至77.5% vs 5.0%(P < .001)。
  • 第12周PASI 100应答率:39.0%至50.0% vs 2.5%(P < .005)。
  • 第12周sPGA 0/1应答率:80.5%至87.5% vs 20.0%(P < .001)。
  • D-2570表现出良好的药代动力学特性,并有效抑制患者IL-17A水平。

关键数值与推荐

  • 主要终点为第12周达到PASI 75的患者比例。
  • 次要终点包括PASI 75/90/100、sPGA 0/1、安全性及药代动力学/药效学特征。

临床怎么用

  • D-2570作为口服TYK2抑制剂,在中重度斑块状银屑病短程12周治疗中显示显著疗效与良好耐受性,支持后续进一步临床开发。

局限性

  • 样本量小,治疗和随访时间相对较短。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: D-2570, a TYK2 inhibitor, is currently being developed for autoimmune diseases including psoriasis and ulcerative colitis. OBJECTIVE: To evaluate the efficacy and safety of D-2570 in patients with moderate-to-severe plaque psoriasis. METHODS: In the randomized, double-blind, phase 2 study (NCT06278350), patients were randomized 1:1:1:1 to receive D-2570 at 18/27/36 mg, or placebo once daily for 12 weeks. The primary endpoint was the proportion of patients achieving psoriasis area severity index (PASI) 75 at week 12. Secondary endpoints included PASI 75/90/100 and static Physician Global Assessment (sPGA) score of 0/1, safety, and pharmacokinetic/pharmacodynamic characteristics. RESULTS: At week 12, significantly higher response rates for PASI 75 (85.0% to 90.0%, vs 12.5%, P < .001 for all), PASI 90 (70.7% to 77.5% vs 5.0%, P < .001), PASI 100 (39.0% to 50.0% vs 2.5%, P < .005) and sPGA 0/1 (80.5% to 87.5% vs 20.0%, P < .001) were achieved in patients receiving D-2570 at 18/27/36 mg versus placebo. D-2570 was well tolerated, and most treatment-emergent adverse events were mild/moderate. D-2570 exhibited favorable pharmacokinetic properties and effectively suppressed IL-17A levels in patients. LIMITATIONS: Small sample size, relatively short duration of treatment and follow-up. CONCLUSION: D-2570 demonstrated a high efficacy with favorable safety profile in patients with moderate-to-severe plaque psoriasis.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Zhang J, Zhou C, Miao G, et al. Novel TYK2 inhibitor D-2570 in moderate-to-severe plaque psoriasis: A randomized, double-blind, placebo-controlled, phase 2 trial. J Am Acad Dermatol. 2025. PMID: 40967307. doi:10.1016/j.jaad.2025.09.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。